ISIN:US09076G1040

Biophytis announces the drawing of the second tranche of ORNANE under the 2021 Atlas Contract for €4 million

Retrieved on: 
Jeudi, juin 30, 2022 - 10:08pm
Review, Nasdaq, Ageing, Patient, Euronext Growth, Ticker, ADSS, COVID-19, DMD, Company, Risk, Forward-looking statement, Duchenne muscular dystrophy, U.S. Securities and Exchange Commission, Therapy, Sarcopenia, American depositary receipt, SEC, Security (finance), Pharmaceutical industry, Audit

It is also being studied in a clinical two-part Phase 2-3 study (COVA) for the treatment of severe respiratory manifestations of COVID-19 in Europe, Latin America, and the US.

Key Points: 
  • It is also being studied in a clinical two-part Phase 2-3 study (COVA) for the treatment of severe respiratory manifestations of COVID-19 in Europe, Latin America, and the US.
  • A pediatric formulation of Sarconeos (BIO101) is being developed for the treatment of Duchenne Muscular Dystrophy (DMD).
  • Such forward-looking statements are based on assumptions that Biophytis considers to be reasonable.
  • The forward-looking statements contained in this press release are also subject to risks not yet known to Biophytis or not currently considered material by Biophytis.

Biophytis presents the development of Sarconeos (BIO101) in Phase 3 for the treatment of Sarcopenia at the 15th SCWD International Congress

Retrieved on: 
Lundi, juin 27, 2022 - 10:05pm
Review, FDA, Ageing, Patient, CEO, Cachexia, Euronext Growth, International, Ticker, ADS, Society, Degenerative disease, COVID-19, Company, Disease, AMF, Society on Sarcopenia, Cachexia and Wasting Disorders, DMD, CET, Forward-looking statement, Duchenne muscular dystrophy, U.S. Securities and Exchange Commission, Hope, PRO, EMA, Risk, Therapy, CTA, LIFE, Clinical trial, Parallel Walk Test, American depositary receipt, SARA, HGS, SEC, Congress, DRS, Shear strength, Outline, Adapted automobile, Patient-reported outcome, Security (finance), Pharmaceutical industry, Medical device, Health insurance, Sarcopenia, European, Nasdaq

Sarconeos (BIO101) has the potential to be the first drug candidate ever moving into Phase 3 in Sarcopenia.

Key Points: 
  • Sarconeos (BIO101) has the potential to be the first drug candidate ever moving into Phase 3 in Sarcopenia.
  • The design of this study may however evolve depending on the discussions currently underway with the European and American health authorities.
  • Sarconeos (BIO101), our leading drug candidate, is a small molecule, administered orally,) just achieved its phase 2 development as a treatment for sarcopenia in the United States and Europe (SARA-INT).
  • A pediatric formulation of Sarconeos (BIO101) is being developed for the treatment of Duchenne Muscular Dystrophy (DMD).

Biophytis: Results of the Combined General Meeting on June 21, 2022 All ordinary and extraordinary resolutions presented by the company have been adopted

Retrieved on: 
Mercredi, juin 22, 2022 - 10:07pm
General assembly, Review, ADSS, Investor, Security (finance), Therapy, COVID-19, Risk, Mass meeting, Ageing, CGM, Duchenne muscular dystrophy, CEO, American depositary receipt, Euronext Growth, Company, U.S. Securities and Exchange Commission, Director, Sarcopenia, Forward-looking statement, Combined, SEC, Ticker, Nasdaq, Degenerative disease, Patient, Board of directors, DMD, Medical device, Pharmaceutical industry

The results of the votes of the combined General Meeting will be available on Biophytis website from June 23, 2022, under the section - Investors - General Assembly.

Key Points: 
  • The results of the votes of the combined General Meeting will be available on Biophytis website from June 23, 2022, under the section - Investors - General Assembly.
  • Stanislas Veillet, President, and CEO of Biophytis, said: I would like to thank all the shareholders for their commitment and renewed trust.
  • I am very pleased that all the resolutions presented by the company during the Combined General Meeting were approved by a very large majority.
  • Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements.

Biophytis presents preclinical efficacy data for Sarconeos (BIO101) in Spinal Muscular Atrophy (SMA), a rare neuromuscular disease

Retrieved on: 
Jeudi, juin 16, 2022 - 7:03am
Degenerative disease, Duchenne, Review, Security (finance), Therapy, COVID-19, Spinal muscular atrophy, Ageing, Duchenne muscular dystrophy, CEO, American depositary receipt, Euronext Growth, Neurodegeneration, Company, U.S. Securities and Exchange Commission, Sarcopenia, Forward-looking statement, AMF, ADS, CET, SEC, Ticker, Death, Patient, Life, DMD, Pharmaceutical industry, SMA, Nasdaq

Stanislas Veillet, CEO of Biophytis, said: "We are very pleased to present this work to the SMA community.

Key Points: 
  • Stanislas Veillet, CEO of Biophytis, said: "We are very pleased to present this work to the SMA community.
  • These new data highlight the full potential of Sarconeos (BIO101) beyond age-related diseases (sarcopenia and COVID-19) for which it is in late stage clinical development.
  • Biophytis is currently preparing the start of the MYODA clinical program in the Duchenne Muscular Dystrophy for late 2022/early 2023."
  • SMA is a rare progressive neurodegenerative disease that robs an individual of the ability to walk, eat and breathe.

Biophytis: Convening of Another Combined General Meeting at a Later Date

Retrieved on: 
Mardi, juin 7, 2022 - 5:56am
Duchenne muscular dystrophy, Company, CET, U.S. Securities and Exchange Commission, Forward-looking statement, Security (finance), Euronext Growth, Therapy, DMD, Sarcopenia, Mass meeting, Patient, AMF, Review, COVID-19, Ticker, ADS, SEC, AGM, Internet, American depositary receipt, Ageing, Pharmaceutical industry, Holding company, Nasdaq

The shareholders taking part in the vote owned collectively 23 514 980 shares, or 15.45% of the share capital, and 16.19% of the voting rights.

Key Points: 
  • The shareholders taking part in the vote owned collectively 23 514 980 shares, or 15.45% of the share capital, and 16.19% of the voting rights.
  • The 20% quorum necessary for holding an ordinary AGM on first call and the 25% quorum necessary for holding an extraordinary General Meeting on first call have not been reached.
  • Shareholders will therefore be invited to another combined AGM, on the second call, to be held at a later date with the same agenda.
  • The vote of shareholders who submitted their vote via the post, email or the Internet for the first general meeting remains valid and counted for the general meeting on the second call.